{"id":1068383,"date":"2022-12-24T00:13:07","date_gmt":"2022-12-24T05:13:07","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/biontech-initiates-phase-1-clinical-trial-for-malaria-vaccine-program-bnt165\/"},"modified":"2024-08-18T11:46:33","modified_gmt":"2024-08-18T15:46:33","slug":"biontech-initiates-phase-1-clinical-trial-for-malaria-vaccine-program-bnt165","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/biontech-initiates-phase-1-clinical-trial-for-malaria-vaccine-program-bnt165.php","title":{"rendered":"BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165"},"content":{"rendered":"<p><![CDATA[MAINZ, Germany, December 23, 2022 \u2013 BioNTech SE (Nasdaq: BNTX, \u201cBioNTech\u201d, \"the Company\") today announced the initiation of a first-in-human Phase 1 study with BNT165b1, the first candidate from the Company\u2019s BNT165 program, to develop a multi-antigen malaria vaccine candidate. BioNTech will initially evaluate a set of mRNA-encoded antigens of the malaria-causing parasite Plasmodium falciparum (P. falciparum) to help select the multi-antigen vaccine candidate to proceed to planned later-stage trials. This first clinical trial (NCT05581641) will evaluate the safety, tolerability and exploratory immunogenicity of the vaccine candidate BNT165b1. BNT165b1 expresses certain parts of the circumsporozoite protein (CSP).]]><\/p>\n<p>See the article here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/12\/23\/2579011\/0\/en\/BioNTech-Initiates-Phase-1-Clinical-Trial-for-Malaria-Vaccine-Program-BNT165.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165\">BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See the article here: BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165 <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/biontech-initiates-phase-1-clinical-trial-for-malaria-vaccine-program-bnt165.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068383","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068383"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068383"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068383\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}